PT-141 10mg

Contents

Use this guide as a structured review page. The same headings appear for every protocol so clients and the care team can scan the page consistently.

Quickstart Highlights

PT‑141 (bremelanotide) is a melanocortin receptor agonist that acts centrally—predominantly via MC4R—to influence sexual desire pathways[7][8]. The FDA‑approved subcutaneous regimen for HSDD is a single 1.75 mg injection as needed (PRN), administered at least 45 minutes before anticipated sexual activity; do not exceed one dose per 24 hours or eight doses per month[1]. The table below presents practical per‑administration measurements using a clear insulin‑syringe dilution.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
• Per‑administration range (for titration): 500–1,750 mcg (0.5–1.75 mg), with 1.75 mg as the standard PRN dose in trials and labeling[1][2]. Open source
• Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U‑100 insulin syringe.
• Storage (general biologic handling): Lyophilized materials are commonly kept cold for long‑term stability (≤ −20 °C (≤ −4 °F))[13]; reconstituted peptide solutions are commonly held refrigerated short‑term at 2–8 °C (35.6–46.4 °F)[14]. Avoid repeated freeze–thaw. Open source

Dosing & Reconstitution Guide

Route: Subcutaneous (abdomen or thigh). Frequency: PRN only — 1 dose ≥45 minutes before activity; max 1/24 h and ≤8/month[1]. Volume tolerance: SC injections of up to ~3.0 mL are generally well‑tolerated in the abdomen[5][6].

• Important: Table shows per‑administration doses (not daily therapy). Do not exceed one dose within 24 hours or more than eight doses per month; reassess benefit after ~8 weeks of use per labeling[1].

Reconstitution Steps

Reference-derived details for PT-141 10mg.

• Using sterile technique, draw 3.0 mL bacteriostatic water.
• Inject slowly down the vial wall; avoid foaming.
• Gently swirl/roll until dissolved (do not shake).
• Label and refrigerate at 2–8 °C (35.6–46.4 °F); protect from light[14]. Open source

Supplies Needed

Plan based on PRN use (≤8 doses/month) with a 1.75 mg standard dose[1]. At this dilution, each 10 mg vial provides 5 full doses (0.525 mL per dose × 5 = 2.625 mL used; a sixth would exceed 3.0 mL).

• Peptide Vials (PT‑141, 10 mg each):Note: Counts round up to ensure full‑volume doses at 1.75 mg each.
• Peptide Vials (PT‑141, 10 mg each):Note: Counts round up to ensure full‑volume doses at 1.75 mg each.: 8 weeks (~16 doses): 4 vials
• Peptide Vials (PT‑141, 10 mg each):Note: Counts round up to ensure full‑volume doses at 1.75 mg each.: 12 weeks (~24 doses): 5 vials
• Peptide Vials (PT‑141, 10 mg each):Note: Counts round up to ensure full‑volume doses at 1.75 mg each.: 16 weeks (~32 doses): 7 vials
• Insulin Syringes (U‑100):
• Insulin Syringes (U‑100):: Per dose: 1 syringe (single‑use)
• Insulin Syringes (U‑100):: 8 weeks: 16 syringes
• Insulin Syringes (U‑100):: 12 weeks: 24 syringes
• Insulin Syringes (U‑100):: 16 weeks: 32 syringes
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.: 4 vials: 12 mL total → 2 × 10 mL bottles
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.: 5 vials: 15 mL total → 2 × 10 mL bottles
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.: 7 vials: 21 mL total → 3 × 10 mL bottles
• Alcohol Swabs: One for the vial stopper + one for the injection site per dose.
• Alcohol Swabs: One for the vial stopper + one for the injection site per dose.: 8 weeks: 32 swabs
• Alcohol Swabs: One for the vial stopper + one for the injection site per dose.: 12 weeks: 48 swabs
• Alcohol Swabs: One for the vial stopper + one for the injection site per dose.: 16 weeks: 64 swabs

Protocol Overview

Concise summary of PRN subcutaneous use.

• Goal: Improve sexual desire and reduce related distress in premenopausal women with HSDD, as shown in two Phase 3 RECONNECT trials[2]. Open source
• Schedule: PRN subcutaneous dosing—1.75 mg at least 45 minutes before anticipated activity; limit 1 dose per 24 h and ≤8/month; reassess after ~8 weeks[1]. Open source
• Per‑administration Range: 0.5–1.75 mg depending on response/tolerability, with 1.75 mg as the standard labeled dose[1]. Open source
• Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for straightforward unit measurements.
• Storage: Lyophilized cold (≤ −20 °C / ≤ −4 °F) and reconstituted refrigerated at 2–8 °C (35.6–46.4 °F) per general biologic stability practices[13][14]. Open source

Dosing Protocol

Guidance for practical, safe use with clarity on limits.

• Start & Titrate: Consider a conservative trial (e.g., 0.5–1.0 mg) and titrate toward 1.75 mg PRN based on effect and tolerability[1]. Open source
• Do not exceed: 1 dose per 24 h or more than 8 doses per month (higher frequency increased focal hyperpigmentation in studies)[1]. Open source
• Timing: Inject ~45–60 minutes before anticipated activity; some individuals may adjust timing based on personal response[1]. Open source

Storage Instructions

General handling principles for peptide materials.

• Lyophilized: Cold, dark storage is commonly used for long‑term stability (≤ −20 °C / ≤ −4 °F); minimize moisture/light exposure[13]. Open source
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) for short‑term holding; avoid repeated freeze–thaw[14]. Open source

Important Notes

Practical considerations for consistent technique and safety.

• Use new sterile insulin syringes and dispose of sharps appropriately; follow aseptic preparation[3]. Open source
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local reactions and maintain absorption[3][11]. Open source
• Insert at 45–90° into subcutaneous tissue; do not aspirate for SC injections[3][4][10]. Open source
• Common adverse effects include nausea, flushing, headache, and transient blood‑pressure increases; consider cardiovascular risk and labeled precautions[1]. Open source

How This Works

Bremelanotide activates central melanocortin receptors—especially MC4R—in hypothalamic circuits linked to sexual desire and autonomic arousal[7][8]. Two Phase 3 trials demonstrated improvements in validated desire/distress measures versus placebo with PRN 1.75 mg SC dosing[2]. Exploratory metabolic work also suggests MC4R agonism can reduce caloric intake and modestly affect weight in obese adults under intensive dosing schedules[9]. SC delivery is widely used for biologics and supports practical at‑home administration with volumes ≤~3 mL when appropriately sited[5][6].

Lifestyle Factors

Complementary strategies for best outcomes.

• Communicate timing and expectations clearly with partners to align use with anticipated activity.
• Support overall well‑being (sleep, stress, exercise) to improve adherence and perceived benefit.

Potential Benefits & Side Effects

Reference-derived details for PT-141 10mg.

• Improves sexual desire and reduces related distress in premenopausal women with HSDD (Phase 3 evidence)[2]. Open source
• Mechanistic and early human data indicate appetite‑suppressive effects via MC4R activation (magnitude varies by regimen)[8][9]. Open source
• Common AEs: nausea, flushing, headache, injection‑site reactions; transient increases in blood pressure and reduction in heart rate are described in labeling[1]. Open source
• Exceeding labeled frequency (e.g., daily use) increased risk of focal hyperpigmentation in studies—adhere to PRN limits[1]. Open source

Injection Technique

Evidence‑based points from public‑health and clinical sources.

• Clean vial stopper and skin with alcohol; allow to dry[3][10]. Open source
• Pinch a skinfold; insert needle at 45–90° into subcutaneous tissue; inject slowly and steadily[3][4][10]. Open source
• Do not aspirate for SC injections; rotate sites systematically (abdomen, thigh, upper arm)[3][4][11]. Open source

Recommended Source

We recommend Prime Lab Peptides for high‑purity PT‑141 (10 mg).

• High‑purity lots with batch COAs and consistent handling.
• Reliable fulfillment and documentation.
• Product ID: PT-141 10 mg
• Shop at Prime Lab Peptides

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

• Do not start, stop, combine, or change a protocol based only on website content.
• Emergency symptoms require urgent medical care, not a website or routine follow-up message.

References

Reference-derived details for PT-141 10mg.

• PT-141 (10mg Vial) Open source
• FDA Prescribing Information (2019) — Vyleesi (bremelanotide) label: PRN 1.75 mg SC, timing, monthly limit, precautions. View Source Open source
• Obstetrics & Gynecology (2019) — Two Phase 3 RECONNECT trials of bremelanotide 1.75 mg SC PRN for HSDD. View Source Open source
• CDC — Vaccine Administration (2024) — Subcutaneous technique overview (angle, site selection, needle guidance). View Source Open source
• CDC — Subcutaneous Injection Guide (2024, PDF) — 45° insertion, no aspiration for SC injections (diagram & steps). View Source Open source
• Usach et al., Adv Ther (2019) — Subcutaneous injection review: typical and upper‑range volumes; pain considerations. View Source Open source
• Badkar et al., AAPS/Pharmaceutics Review (2021) — High‑dose/volume SC delivery; practical upper volumes near ~3 mL. View Source Open source
• Sharma et al., Front Neurosci (2019) — MC4R pathway mechanisms and therapeutic targeting relevant to desire/arousal. View Source Open source
• Fansa et al., Int J Obes (2024) — MC4R pathway in appetite/energy balance; central melanocortin signaling overview. View Source Open source
• Spana et al., Diabetes Obes Metab (2022) — Phase 1: Bremelanotide reduced caloric intake and body weight under intensive dosing. View Source Open source
• MedlinePlus (NIH) — Patient instructions for subcutaneous injections (angle, site rotation, hygiene). View Source Open source
• Hirsch, Diabetes Ther (2019) — Injection technique factors; systematic site rotation to avoid lipohypertrophy. View Source Open source
• Prime Lab Peptides — PT‑141 (10 mg) product page (supplier details). View Source Open source
• NIBSC (UK) — Peptide handling: dry/lyophilized peptides best preserved cold; long‑term at about −20 °C. View Source Open source
• Cheng et al., AAPS Open (2024) — Lyophilized protein drug products; reconstituted liquid stability commonly assessed at 2–8 °C. View Source Open source